



Fate Therapeutics, Inc.
Investor Relations Department
3535 General Atomics Ct.
Suite 200
San Diego, CA 92121
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: FATE

| | |
|---------------|----------------------------|
| Last Trade: | 4.37 |
| Trade Time: | 4:00 PM ET Nov 17, 2017 |
| Change: | 0.05 (+1.157%) |
| Day Range | 4.26 - 4.45 |
| 52-Week Range | 2.40 - 5.68 |
| Volume | 91,964 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Nov 10, 2017

[Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for Relapsed / Refractory Acute Myelogenous Leukemia at SITC 2017 Annual Meeting](#)

Nov 1, 2017

[Fate Therapeutics Reports Third Quarter 2017 Financial Results](#)

Nov 1, 2017

[Fate Therapeutics Announces Six Presentations at the 2017 ASH Annual Meeting](#)

Oct 25, 2017

[Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2017 Financial Results](#)

Sep 18, 2017

[Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Mar 22, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 1, 2017

[Quarterly Report \(10-Q\)](#)

Aug 14, 2017

[Quarterly Report \(10-Q\)](#)

May 15, 2017

[Quarterly Report \(10-Q\)](#)